Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Auric Goldfinger's Short List -- Ignore unavailable to you. Want to Upgrade?

To: Jim Roof who wrote (738)	11/17/1998 11:49:00 AM
From: Kevin Podsiadlik	Read Replies (1) \| Respond to of 19428

If you're going to insist on sticking around, then perhaps you would be so kind as to answer a few questions about BTIM. For starters: Is it true or false, that Biotime president Ronald Barkin stated that Biotime's "belief is that [the FDA] will treat [Hextend's application] in an expedited manner and that we will get a six-month review and we do believe that we will get an actual letter from the FDA in September or October of this year," on July 14th of this year at a Montgomery Securities health conference? And it is true or false, that on October 26th, that Mr. Barkin told Reuters, "The company has never said we were being given an expedited review" of Hextend, and stated that the review may take as long as eighteen months to complete? Do not take too terribly long on these questions, I have more.